In focus · trending topic

natural killer cells

2 stories · following the connections

Nkarta Therapeutics Appoints Veteran Executive Paul Hastings as CEO to Lead Next Phase of Growth

By Nasdaq OMXMar 1, 2018, 7:05 PM UTC

Fate Therapeutics Announces Oral Presentation on Natural Killer Cell Product Candidate FATE-NK100 at the 2016 ASH Annual Meeting

By Nasdaq OMXNov 3, 2016, 8:59 PM UTC